Sign in

You're signed outSign in or to get full access.

Daniel Coyle

Chief Operating Officer at SANUWAVE Health
Executive

About Daniel Coyle

Daniel Coyle, age 35, was appointed Chief Operating Officer (COO) of SANUWAVE Health, Inc. on September 25, 2025, after serving as Vice President of Engineering and Operations from October 2024 to September 2025; prior to SANUWAVE he was a Program Director at Nextern, a medical device manufacturer, from September 2019 through September 2024 . His compensation is structured with a modest base salary and bonus opportunity plus material option-based equity that vests quarterly, intended to align with operational execution; company option programs in 2025 included service-, performance-, and market-based awards with conditions tied to revenue, adjusted EBITDA, NASDAQ uplisting, debt refinancing, operational milestones, and stock price targets .

Past Roles

OrganizationRoleYearsStrategic impact
SANUWAVE Health, Inc.Vice President of Engineering and OperationsOct 2024 – Sep 2025Led engineering and operations; positioned for promotion to COO
SANUWAVE Health, Inc.Chief Operating OfficerSep 25, 2025 – PresentExecutive operations leadership; compensation realigned to COO scope
Nextern (medical device manufacturer)Program DirectorSep 2019 – Sep 2024Managed device programs; operational experience relevant to SANUWAVE

External Roles

OrganizationRoleYearsNotes
NexternProgram DirectorSep 2019 – Sep 2024Medical device programs and operations

Fixed Compensation

ComponentValueEffective dateNotes
Base salary$225,000Sep 25, 2025Increased upon appointment as COO
Target bonus %40% of annual base (prorated for remainder of 2025)Sep 25, 2025Annual cash bonus opportunity increased with appointment

Performance Compensation

Option Awards – Service-Based (Time-Vesting)

Grant dateTypeNumber of sharesStrike priceExpirationVesting scheduleStatus/Notes
Oct 22, 2024Stock Option (right to buy)20,000$14.20Oct 22, 2034Vests over 3 years in 12 equal quarterly installmentsReported on Form 3; owned directly
Oct 9, 2025Stock Option (right to buy)60,000Vests and becomes exercisable in 12 equal quarterly installments from grant dateApproved with COO appointment; grant date specified; price not disclosed

Option Awards – Performance-Based

Grant dateTypeNumber of sharesStrike priceExpirationPerformance metric(s)Vesting status
Jun 4, 2025Stock Option (right to buy)10,000$27.00Jun 4, 2035Four project-based performance milestones2 of 4 milestones met; 5,000 options vested

Company-wide 2025 performance/market award conditions included: revenue recognized, adjusted EBITDA targets, NASDAQ listing, debt refinancing, various operations milestones, and a stock price target; vesting occurs upon condition achievement and expense recognized accordingly (market-based awards amortized over requisite service period) .

Equity Ownership & Alignment

CategoryAmountDetails
Common shares beneficially owned37Direct ownership as of Form 3 (event date 10/01/2025)
Options – Oct 22, 2024 grant20,000$14.20 strike; expires 10/22/2034; quarterly vest over 3 years
Options – Jun 4, 2025 grant10,000$27.00 strike; expires 06/04/2035; project milestone vesting (5,000 vested)
Options – Oct 9, 2025 grant60,000Quarterly vest; exercise price at grant FMV; expiration not disclosed
Pledging/HedgingCompany policy restricts pledging/hedging and enforces ownership and holding guidelines for plan participants
Clawback & forfeitureAwards subject to forfeiture and recovery; automatic amendment to comply with SEC Rule 10D and applicable listing rules

Employment Terms

TermDetails
AppointmentAppointed COO on Sep 25, 2025; no special arrangements/understandings for selection; no family relationships or related party interests disclosed
Compensation actionsBase salary set at $225,000; annual bonus opportunity set at 40% (prorated for remainder of 2025); option award of 60,000 shares granted Oct 9, 2025 with quarterly vesting
Severance/change-of-controlNot disclosed for Coyle; no specific severance or CoC provisions cited in his appointment 8-K
Clawback & adverse conduct remediesPlan provides forfeiture/recovery for cause, policy violations, breach of restrictive covenants, incorrect performance determinations, or detrimental conduct; compliance with SEC/stock exchange clawbacks
Repricing protectionPlan prohibits option/SAR repricing without stockholder approval

Compensation Structure Analysis

  • Equity-heavy, retention-oriented design: Quarterly vesting across 3 years for the Oct 2024 and Oct 2025 service-based grants creates steady retention hooks and staggered potential Form 4 “M” exercises; performance-based grant (Jun 2025) ties vesting to measurable project milestones, with half already achieved (5,000 vested) .
  • Performance alignment: Company’s 2025 awards incorporate financial and strategic milestones (revenue, adjusted EBITDA, NASDAQ listing, debt refinancing, operational goals, stock price target), indicating emphasis on both operating execution and capital/market objectives .
  • Governance protections: Clawback, forfeiture, and anti-repricing provisions, plus policies restricting pledging/hedging and enforcing ownership/holding guidelines, mitigate shareholder risk from misaligned pay outcomes .

Risk Indicators & Context

  • Insider/related-party: No related-party transactions or selection arrangements disclosed for Coyle; no family relationships with executives/directors .
  • Organizational change: His appointment coincided with a leadership transition (former COO reassigned, President terminated without cause), suggesting an active restructuring period that can elevate execution risk but may also reflect strategic realignment .
  • Equity plan capacity and governance: Shareholders approved adding 500,000 shares to the 2024 Equity Incentive Plan on Aug 19, 2025, sustaining ability to grant equity while maintaining clawback and anti-repricing safeguards .

Investment Implications

  • Alignment and retention: Quarterly vesting service-based options plus milestone-driven awards suggest durable retention and clear operational focus; the recent 60,000-share grant reinforces COO-level engagement tied to ongoing execution .
  • Limited near-term selling pressure: Form 3 indicates minimal common share ownership (37 shares) with equity largely in options; our document search returned no sale transactions, and vesting is staged, which typically tempers immediate selling pressure absent significant option exercises or withholding events .
  • Performance catalysts: Company conditions achieved (NASDAQ listing, debt refinancing) and remaining targets (revenue, adjusted EBITDA, operational milestones, stock price) provide identifiable triggers for incremental vesting and potential comp expense recognition—monitor disclosures for additional milestone attainment and any Form 4 filings .
  • Governance safeguards: Robust clawback/forfeiture and anti-repricing features, plus restrictions on pledging/hedging, are shareholder-friendly and reduce pay-for-performance slippage risk .